Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction
- PMID: 12440226
- DOI: 10.1046/j.1359-4117.2002.01062.x
Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction
Abstract
In a recent study on head and neck squamous cell carcinoma (HNSCC) cells we found that epigallocatechin-3-gallate (EGCG), a major biologically active component of green tea, inhibited activation of the epidermal growth factor receptor (EGFR) and related signaling pathways. Since activation of EGFR signaling pathways is associated with angiogenesis, we examined the effects of EGCG on vascular endothelial growth factor (VEGF) production by YCU-H891 HNSCC and MDA-MB-231 breast carcinoma cell lines, because we found that both of these cell lines display autocrine activation of transforming growth factor-alpha (TGF-alpha)/EGFR signaling and produce high levels of VEGF. Treatment with EGCG inhibited the constitutive activation of the EGFR, Stat3, and Akt in both cell lines. These changes were associated with inhibition of VEGF promoter activity and cellular production of VEGF. Mechanistic studies indicated that inhibition of Stat3, but not mitogen-activated protein kinase kinase (MEK)1 or phosphatidylinositol 3'-kinase (PI3K), significantly decreased VEGF promoter activity. However, the inhibitory effects of a dominant negative Stat3 on VEGF expression was not as strong as that produced by EGCG. An analysis of alternative pathways indicated that EGCG strongly inhibited the constitutive activation of NF-kappa B in both cell lines, and an NF-kappa B inhibitor strongly inhibited VEGF production. These results suggest that EGCG inhibits VEGF production by inhibiting both the constitutive activation of Stat3 and NF-kappa B, but not extracellular-signal-regulated kinase (ERK) or Akt, in these cells. Therefore, EGCG may be useful in treating HNSCC and breast carcinoma because it can exert both antiproliferative and antiangiogenic activities.
Similar articles
-
Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer.Molecules. 2020 Jan 22;25(3):467. doi: 10.3390/molecules25030467. Molecules. 2020. PMID: 31979082 Free PMC article. Review.
-
Multitargeted therapy of cancer by green tea polyphenols.Cancer Lett. 2008 Oct 8;269(2):269-80. doi: 10.1016/j.canlet.2008.04.014. Epub 2008 May 22. Cancer Lett. 2008. PMID: 18501505 Free PMC article. Review.
-
Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines.Int J Cancer. 2002 Jun 1;99(4):538-48. doi: 10.1002/ijc.10398. Int J Cancer. 2002. PMID: 11992543
-
Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.Cancer Res. 2001 Aug 1;61(15):5911-8. Cancer Res. 2001. PMID: 11479233
-
Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.Clin Cancer Res. 2001 Feb;7(2):435-42. Clin Cancer Res. 2001. PMID: 11234901
Cited by
-
Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets.Molecules. 2024 Mar 20;29(6):1373. doi: 10.3390/molecules29061373. Molecules. 2024. PMID: 38543009 Free PMC article. Review.
-
Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs.Cancer Cell Int. 2023 Oct 14;23(1):241. doi: 10.1186/s12935-023-03081-8. Cancer Cell Int. 2023. PMID: 37838685 Free PMC article. Review.
-
Substances of Natural Origin in Medicine: Plants vs. Cancer.Cells. 2023 Mar 23;12(7):986. doi: 10.3390/cells12070986. Cells. 2023. PMID: 37048059 Free PMC article. Review.
-
Agri-Food By-Products in Cancer: New Targets and Strategies.Cancers (Basel). 2022 Nov 10;14(22):5517. doi: 10.3390/cancers14225517. Cancers (Basel). 2022. PMID: 36428610 Free PMC article. Review.
-
Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha.Front Oncol. 2022 May 18;12:837408. doi: 10.3389/fonc.2022.837408. eCollection 2022. Front Oncol. 2022. PMID: 35664773 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous